Date
- 2026 (27)
- 2025 (31)
- 2024 (17)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (36)
- 2014 (10)
- 2013 (12)
- 2012 (3)
- 2011 (6)
- 2010 (27)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (10)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (3)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (12)
Sponsor content
581 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TABRECTA capmatinib (as hydrochloride) 150 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TABRECTA capmatinib (as hydrochloride) 200 mg tablet blister pack.
-
Prescription medicine decision summaryRhapsido has been approved for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Rhapsido contains the active ingredient remibrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RHAPSIDO remibrutinib 25 mg tablet blister pack.
-
May-2026Prescription medicine evaluationActive ingredient: ianalumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 150 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CEAHANI nilotinib 200mg capsules blister pack.
-
Prescription medicine registrationActive ingredients: remibrutinib.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd